According to InvestingPro analysis, GSK maintains a "GREAT" financial health score, positioning it well for continued pharmaceutical innovation. If approved, depemokimab would be the first ultra ...

GSK will incorporate the findings into messaging that depemokimab patients will adhere to treatment better, ensuring better ...

GSK has made a new drug submission (NDS) to Health Canada for the monoclonal antibody, depemokimab, targeting two specific ...

Depemokimab reduces exacerbations regardless of baseline asthma control, suggesting uncontrolled symptoms are not necessary ...

GSK's experimental IL-5 inhibitor depemokimab has shown its potential in a pair of phase 3 trials in patients with chronic rhinosinusitis with nasal polyps (CRSwNP). The company said this morning ...

Mississauga, Ontario Tuesday, May 27, 2025, 16:00 Hrs [IST] ...

With Sunday’s Academy Awards ceremony in the rearview mirror, GSK is looking ahead to a potential blockbuster premiere of its own. The British Big Pharma has filed depemokimab for FDA approval ...

GSK plc GSK announced positive data from the phase III ANCHOR-1 and ANCHOR-2 studies, which evaluated its pipeline candidate, depemokimab, for treating adults with chronic rhinosinusitis with ...

Key drugs Blenrep and Depemokimab show significant potential, with impressive Phase 3 results, expected to boost GSK's revenues by an extra £7 billion. Despite some IRA and clinical trial risks ...

GSK’s blockbuster hopes for depemokimab remain on track after the investigational long-acting asthma treatment has also been shown to reduce nasal polyps in a pair of phase 3 trials. The ANCHOR ...

UK-based pharmaceutical company GSK has announced positive results from the Phase III ANCHOR-1 and ANCHOR-2 clinical trials of depemokimab in adults with chronic rhinosinusitis with nasal polyps ...

GSK's phase 3 trials ANCHOR-1 and ANCHOR-2 met co-primary endpoints for treating CRSwNP with depemokimab. Adverse event rates were similar between depemokimab and placebo in the trials.